| Not Yet Recruiting | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients Wi NCT07498335 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. NCT07375758 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of Ravulizumab in Pediatric Participants With Primary IgAN NCT07024563 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (Ig NCT06952426 | Novartis Pharmaceuticals | — |
| Recruiting | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With Ig NCT06797518 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy NCT06635772 | Hansoh BioMedical R&D Company | Phase 2 |
| Active Not Recruiting | Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) NCT06564142 | Alpine Immune Sciences Inc, A Subsidiary of Vertex | Phase 3 |
| Recruiting | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) NCT06291376 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy NCT05834738 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Study of Zigakibart in Adults With IgA Nephropathy NCT05852938 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants Wi NCT05856760 | Travere Therapeutics, Inc. | Phase 2 |
| Recruiting | Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Ne NCT04662723 | Fondazione Schena | Phase 4 |
| Active Not Recruiting | An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases NCT05732402 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy NCT05248659 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) NCT05248646 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy NCT05162066 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) NCT05200871 | Travere Therapeutics, Inc. | — |
| Terminated | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) NCT05097989 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Unknown | The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephr NCT05132621 | Medical University of Warsaw | — |
| Recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986 | Travere Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Atrasentan in Patients With Proteinuric Glomerular Diseases NCT04573920 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) NCT04564339 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Active Not Recruiting | Atrasentan in Patients With IgA Nephropathy NCT04573478 | Chinook Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A NCT04663204 | University of Leicester | Phase 2 |
| Completed | Safety and Efficacy Study of VIS649 for IgA Nephropathy NCT04287985 | Visterra, Inc. | Phase 2 |
| Active Not Recruiting | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy NCT03762850 | Travere Therapeutics, Inc. | Phase 3 |
| Completed | First in Human Study to Assess Safety of VIS649 in Healthy Subjects NCT03719443 | Visterra, Inc. | Phase 1 |
| Withdrawn | Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy NCT02605525 | Baxalta now part of Shire | Phase 2 |
| Completed | Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blo NCT02384317 | Amgen | Phase 2 |
| Completed | Development of a Metabolic Assessment Tool for Chronic Kidney Disease NCT01838239 | University of California, Davis | N/A |